Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 628

1.

Prognostic factors in 161 patients with mucosal melanoma: a study of German Central Malignant Melanoma Registry.

Sarac E, Amaral T, Keim U, Leiter U, Forschner A, Eigentler TK, Garbe C.

J Eur Acad Dermatol Venereol. 2020 Feb 20. doi: 10.1111/jdv.16306. [Epub ahead of print]

PMID:
32078189
2.

Absolute and relative differential blood count predicts survival of AJCC stage I-II melanoma patients scheduled for sentinel lymph node biopsy.

Wagner NB, Luttermann F, Gassenmaier M, Forschner A, Leiter U, Garbe C, Eigentler TK.

Australas J Dermatol. 2020 Feb 12. doi: 10.1111/ajd.13248. [Epub ahead of print]

PMID:
32050042
3.

Posteriores reversibles Enzephalopathie-Syndrom bei einem Melanompatienten unter Dabrafenib- und Trametinib-Behandlung nach Immuntherapie.

Stefanou MI, Gepfner-Tuma I, Brendle C, Kowarik M, Meiwes A, Eigentler T, Müller A, Garbe C, Ziemann U, Tabatabai G, Forschner A.

J Dtsch Dermatol Ges. 2020 Feb;18(2):136-139. doi: 10.1111/ddg.13991_g. German. No abstract available.

PMID:
32026643
4.

Sonidegib and vismodegib in the treatment of patients with locally advanced basal cell carcinoma: a joint expert opinion.

Dummer R, Ascierto PA, Basset-Seguin N, Dréno B, Garbe C, Gutzmer R, Hauschild A, Krattinger R, Lear JT, Malvehy J, Schadendorf D, Grob RJJ.

J Eur Acad Dermatol Venereol. 2020 Jan 28. doi: 10.1111/jdv.16230. [Epub ahead of print] Review.

PMID:
31990414
5.

Pitfalls in the characterization of circulating and tissue-resident human γδ T cells.

Beucke N, Wesch D, Oberg HH, Peters C, Bochem J, Weide B, Garbe C, Pawelec G, Sebens S, Röcken C, Hashimoto H, Löffler MW, Nocerino P, Kordasti S, Kabelitz D, Schilbach K, Wistuba-Hamprecht K.

J Leukoc Biol. 2020 Jan 22. doi: 10.1002/JLB.5MA1219-296R. [Epub ahead of print]

PMID:
31967358
6.

European consensus-based interdisciplinary guideline for melanoma. Part 1: Diagnostics - Update 2019.

Garbe C, Amaral T, Peris K, Hauschild A, Arenberger P, Bastholt L, Bataille V, Del Marmol V, Dréno B, Fargnoli MC, Grob JJ, Höller C, Kaufmann R, Lallas A, Lebbé C, Malvehy J, Middleton M, Moreno-Ramirez D, Pellacani G, Saiag P, Stratigos AJ, Vieira R, Zalaudek I, Eggermont AMM; European Dermatology Forum (EDF), the European Association of Dermato-Oncology (EADO), and the European Organization for Research and Treatment of Cancer (EORTC).

Eur J Cancer. 2020 Feb;126:141-158. doi: 10.1016/j.ejca.2019.11.014. Epub 2020 Jan 9.

7.

Cancer immunotherapy is accompanied by distinct metabolic patterns in primary and secondary lymphoid organs observed by non-invasive in vivo 18F-FDG-PET.

Schwenck J, Schörg B, Fiz F, Sonanini D, Forschner A, Eigentler T, Weide B, Martella M, Gonzalez-Menendez I, Campi C, Sambuceti G, Seith F, Quintanilla-Martinez L, Garbe C, Pfannenberg C, Röcken M, la Fougere C, Pichler BJ, Kneilling M.

Theranostics. 2020 Jan 1;10(2):925-937. doi: 10.7150/thno.35989. eCollection 2020.

8.

Update on tolerability and overall survival in COLUMBUS: landmark analysis of a randomised phase 3 trial of encorafenib plus binimetinib vs vemurafenib or encorafenib in patients with BRAF V600-mutant melanoma.

Ascierto PA, Dummer R, Gogas HJ, Flaherty KT, Arance A, Mandala M, Liszkay G, Garbe C, Schadendorf D, Krajsova I, Gutzmer R, de Groot JWB, Loquai C, Gollerkeri A, Pickard MD, Robert C.

Eur J Cancer. 2020 Feb;126:33-44. doi: 10.1016/j.ejca.2019.11.016. Epub 2020 Jan 2.

9.

European consensus-based interdisciplinary guideline for melanoma. Part 2: Treatment - Update 2019.

Garbe C, Amaral T, Peris K, Hauschild A, Arenberger P, Bastholt L, Bataille V, Del Marmol V, Dréno B, Fargnoli MC, Grob JJ, Höller C, Kaufmann R, Lallas A, Lebbé C, Malvehy J, Middleton M, Moreno-Ramirez D, Pellacani G, Saiag P, Stratigos AJ, Vieira R, Zalaudek I, Eggermont AMM; European Dermatology Forum (EDF), the European Association of Dermato-Oncology (EADO), and the European Organization for Research and Treatment of Cancer (EORTC).

Eur J Cancer. 2020 Feb;126:159-177. doi: 10.1016/j.ejca.2019.11.015. Epub 2019 Dec 19.

10.

Clinical validation of a prognostic 11-gene expression profiling score in prospectively collected FFPE tissue of patients with AJCC v8 stage II cutaneous melanoma.

Amaral TMS, Hoffmann MC, Sinnberg T, Niessner H, Sülberg H, Eigentler TK, Garbe C.

Eur J Cancer. 2020 Jan;125:38-45. doi: 10.1016/j.ejca.2019.10.027. Epub 2019 Dec 12.

11.

Posterior reversible encephalopathy syndrome in a melanoma patient with dabrafenib and trametinib treatment following immunotherapy.

Stefanou MI, Gepfner-Tuma I, Brendle C, Kowarik M, Meiwes A, Eigentler T, Müller A, Garbe C, Ziemann U, Tabatabai G, Forschner A.

J Dtsch Dermatol Ges. 2020 Feb;18(2):136-139. doi: 10.1111/ddg.13991. Epub 2019 Dec 9. No abstract available.

PMID:
31814289
12.

Tumor microenvironment-derived S100A8/A9 is a novel prognostic biomarker for advanced melanoma patients and during immunotherapy with anti-PD-1 antibodies.

Wagner NB, Weide B, Gries M, Reith M, Tarnanidis K, Schuermans V, Kemper C, Kehrel C, Funder A, Lichtenberger R, Sucker A, Herpel E, Holland-Letz T, Schadendorf D, Garbe C, Umansky V, Utikal J, Gebhardt C.

J Immunother Cancer. 2019 Dec 5;7(1):343. doi: 10.1186/s40425-019-0828-1.

13.

Late recurrence of melanoma after 10 years - Is the course of the disease different from early recurrences?

Sarac E, Wilhelmi J, Thomas I, Leiter U, Keim U, Eigentler TK, Garbe C, Amaral T.

J Eur Acad Dermatol Venereol. 2019 Nov 23. doi: 10.1111/jdv.16106. [Epub ahead of print]

PMID:
31758713
14.

Molecular genetics of cutaneous squamous cell carcinoma: perspective for treatment strategies.

Di Nardo L, Pellegrini C, Di Stefani A, Del Regno L, Sollena P, Piccerillo A, Longo C, Garbe C, Fargnoli MC, Peris K.

J Eur Acad Dermatol Venereol. 2019 Nov 20. doi: 10.1111/jdv.16098. [Epub ahead of print] Review.

PMID:
31747091
15.

Adjuvant therapy for cutaneous melanoma: a systematic review and network meta-analysis of new therapies.

Longo C, Pampena R, Lallas A, Kyrgidis A, Stratigos A, Peris K, Garbe C, Pellacani G.

J Eur Acad Dermatol Venereol. 2019 Nov 12. doi: 10.1111/jdv.16074. [Epub ahead of print] Review.

PMID:
31721319
16.

Melanoma-specific survival in patients with positive sentinel lymph nodes: Relevance of sentinel tumor burden.

Satzger I, Leiter U, Gräger N, Keim U, Garbe C, Gutzmer R.

Eur J Cancer. 2019 Dec;123:83-91. doi: 10.1016/j.ejca.2019.07.004. Epub 2019 Oct 31.

PMID:
31677550
17.

Advanced cutaneous squamous cell carcinoma: real world data of patient profiles and treatment patterns.

Amaral T, Osewold M, Presser D, Meiwes A, Garbe C, Leiter U.

J Eur Acad Dermatol Venereol. 2019 Dec;33 Suppl 8:44-51. doi: 10.1111/jdv.15845. Epub 2019 Oct 28.

PMID:
31658392
18.

Harmonisation of Outcome Parameters and Evaluation (HOPE) for actinic keratosis: protocol for the development of a core outcome set.

Heppt MV, Steeb T, Schmitz L, Garbe C, French LE, Leiter U, Berking C.

Trials. 2019 Oct 11;20(1):589. doi: 10.1186/s13063-019-3696-6.

19.

Safety and efficacy of nivolumab in challenging subgroups with advanced melanoma who progressed on or after ipilimumab treatment: A single-arm, open-label, phase II study (CheckMate 172).

Schadendorf D, Ascierto PA, Haanen J, Espinosa E, Demidov L, Garbe C, Guida M, Lorigan P, Chiarion-Sileni V, Gogas H, Maio M, Fierro MT, Hoeller C, Terheyden P, Gutzmer R, Guren TK, Bafaloukos D, Rutkowski P, Plummer R, Waterston A, Kaatz M, Mandala M, Marquez-Rodas I, Muñoz-Couselo E, Dummer R, Grigoryeva E, Young TC, Nathan P.

Eur J Cancer. 2019 Nov;121:144-153. doi: 10.1016/j.ejca.2019.08.014. Epub 2019 Sep 30.

PMID:
31581055
20.

Targeting tumor-resident mast cells for effective anti-melanoma immune responses.

Kaesler S, Wölbing F, Kempf WE, Skabytska Y, Köberle M, Volz T, Sinnberg T, Amaral T, Möckel S, Yazdi A, Metzler G, Schaller M, Hartmann K, Weide B, Garbe C, Rammensee HG, Röcken M, Biedermann T.

JCI Insight. 2019 Oct 3;4(19). pii: 125057. doi: 10.1172/jci.insight.125057.

Supplemental Content

Loading ...
Support Center